Heart failure patients benefit from dapagliflozin after TAVR procedure

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely to die or experience worsening heart failure…

Continue ReadingHeart failure patients benefit from dapagliflozin after TAVR procedure

Investigational drug lorundrostat offers significant blood pressure drop compared with placebo

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented at the American…

Continue ReadingInvestigational drug lorundrostat offers significant blood pressure drop compared with placebo